Upperton to invest $18m in new highly potent facilities

9-Jun-2022

The UK-based specialist pharmaceutical CDMO has announced an $18.8m investment into the design and build of a 50,000 sqft facility designed to handle highly potent molecules and controlled drugs

Upperton Pharma Solutions, a UK-based specialist contract development and manufacturing organisation (CDMO), has announced a circa. £15m ($18.8m) investment into the design and build of a 50,000 sqft facility in Nottingham.

The new facilities will allow a significant increase in research and development laboratory space and a 10-fold increase in GMP manufacturing space.

The site is expected to create 100 job opportunities over the next few years and will strengthen the East Midlands' reputation for accommodating UK scientific centres of excellence.

The space will be designed to handle highly potent molecules and controlled drugs

Scheduled to be completed during the fourth quarter of 2023, the increased capacity will enable Upperton to continue to meet the growing demand for its oral, nasal and pulmonary dosage form development and GMP manufacturing services, as well as expand its offering to support larger scale, later-stage development.

The space will be designed to handle highly potent molecules and controlled drugs, reflecting the increasing number of these molecule types being developed in the industry.

Upperton uses its expertise to develop a wide range of non-sterile, finished dosage formats for its clients. Alongside dosage form development, the company also specialises in spray drying, a particle engineering technology that can be used to ensure targeted delivery of drugs to the lungs and nasal cavity, or to provide solutions to pharma clients who have challenges with poorly soluble molecules.

Like this story? Subscribe to Manufacturing Chemist magazine for the latest news, updates and expert-written articles from the global pharmaceutical and biopharma sectors. For more information click here.

Nikki Whitfield, CEO of Upperton, said: "We are excited to be building new formulation development and analytical laboratories alongside the GMP facility to ensure our operations and capabilities remain state of the art. The new facilities will enable us to increase our current development and manufacturing capacity as well as expand our solid dose and spray drying offerings to address the growing needs of our customers."

The new facilities will also allow Upperton to support existing and new clients further in their product development journey, ensuring a consistent and streamlined pathway to approval.

Sign up for your free email newsletter

Nikki added: "We enjoy close relationships with our clients and want to maintain the scientific and manufacturing support provided in the early stages of their product development through to late stage and commercial."

Featured Companies